These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 32425120)

  • 21. Anti-inflammatory therapies for cardiovascular disease.
    Ridker PM; Lüscher TF
    Eur Heart J; 2014 Jul; 35(27):1782-91. PubMed ID: 24864079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
    Ridker PM
    Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Critical roles of inflammation in atherosclerosis.
    Moriya J
    J Cardiol; 2019 Jan; 73(1):22-27. PubMed ID: 29907363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Old Drugs for New Indications in Cardiovascular Medicine.
    Arbel Y; Abuzeid W; Rosenson RS; Weisman A; Farkouh ME
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):223-232. PubMed ID: 29633048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Colchicine in Reducing Inflammatory Biomarkers and Cardiovascular Risk in Coronary Artery Disease: A Meta-analysis of Clinical Trials.
    Sethuramalingam S; Maiti R; Hota D; Srinivasan A
    Am J Ther; 2023 May; 30(3):e197-e208. PubMed ID: 34264887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel Antiatherosclerotic Therapies.
    Libby P; Everett BM
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):538-545. PubMed ID: 30816799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combating Inflammation in Cardiovascular Disease.
    Sethwala AM; Goh I; Amerena JV
    Heart Lung Circ; 2021 Feb; 30(2):197-206. PubMed ID: 33039279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Utility of Anti-Inflammatory Agents in Cardiovascular Disease: A Novel Perspective on the Treatment of Atherosclerosis.
    Kottoor SJ; Arora RR
    J Cardiovasc Pharmacol Ther; 2018 Nov; 23(6):483-493. PubMed ID: 29783850
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
    Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
    J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colchicine: an affordable anti-inflammatory agent for atherosclerosis.
    Thompson PL; Nidorf SM
    Curr Opin Lipidol; 2018 Dec; 29(6):467-473. PubMed ID: 30320614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of canakinumab for secondary prevention of cardiovascular disease: The Australian healthcare perspective.
    Zomer E; Liew D; Tonkin A; Trauer JM; Ademi Z
    Int J Cardiol; 2019 Jun; 285():1-5. PubMed ID: 30686493
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
    Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
    Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease.
    Nidorf M; Thompson PL
    Am J Cardiol; 2007 Mar; 99(6):805-7. PubMed ID: 17350370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia.
    Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.
    Everett BM; Cornel JH; Lainscak M; Anker SD; Abbate A; Thuren T; Libby P; Glynn RJ; Ridker PM
    Circulation; 2019 Mar; 139(10):1289-1299. PubMed ID: 30586730
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
    Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
    J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canakinumab: Promises and Future in Cardiometabolic Diseases and Malignancy.
    Dhorepatil A; Ball S; Ghosh RK; Kondapaneni M; Lavie CJ
    Am J Med; 2019 Mar; 132(3):312-324. PubMed ID: 30832770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-inflammatory therapy in ischaemic heart disease: from canakinumab to colchicine.
    Andreotti F; Maggioni AP; Campeggi A; Iervolino A; Scambia G; Massetti M
    Eur Heart J Suppl; 2021 Oct; 23(Suppl E):E13-E18. PubMed ID: 34650351
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current pharmacotherapies for atherosclerotic cardiovascular diseases.
    Park JG; Oh GT
    Arch Pharm Res; 2019 Mar; 42(3):206-223. PubMed ID: 30725249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.